GET DAILY SIGNALSWhy Is Karyopharm Therapeutics (KPTI) Stock Down -24.13% Today?
Key Takeaways
- Direction and magnitude: Shares of Karyopharm Therapeutics tumbled about 24.13% in Thursday's session, sliding to roughly $0.0456 from a prior close of $0.0601.
- Primary catalyst: Continued liquidation following the company's Chapter 11 bankruptcy filing and a Nasdaq delisting notice that leaves holders of common stock with no recovery under the restructuring plan.
- Secondary drivers: An expected trading suspension effective November 11 and a move to over-the-counter trading under the symbol "KPTIQ," alongside removals from Russell and S&P benchmark indexes.
- Broader context: The decline reflects distressed micro-cap biotech dynamics rather than broad equity-market weakness.
- What traders are watching next: Bankruptcy-court approval of up to $55 million in debtor-in-possession financing, competing bids for the company's assets, and any update on third-quarter results and the planned Ayrmid merger.
- For deeper detail on Price Targets, Earnings, and Forecast data on this ticker, explore Tickeron's dedicated pages.
- To see how AI-driven strategies are navigating volatile names like this one, explore Trending AI Robots.
Opening Summary
Karyopharm Therapeutics Inc. (KPTI), a Newton, Massachusetts-based commercial-stage oncology company known for its XPO1 inhibitor XPOVIO (selinexor), saw its shares plunge another 24.13% on November 6, 2026. The stock fell to roughly $0.0456 from a prior close of $0.0601, extending a catastrophic multi-day collapse that has wiped out virtually all of the company's remaining equity value. Markets attributed the continued selling to the fallout from Karyopharm's Chapter 11 bankruptcy filing and the company's confirmation that its common stockholders are expected to receive no recovery under the reorganization plan.
Catalyst Breakdown: Chapter 11 and an Equity Wipeout
The overriding driver behind the collapse is structural rather than operational. On November 2, 2026, KPTI and its subsidiary KPT Texas LLC filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas, while announcing a planned merger with Ayrmid Ltd., the parent company of cell-therapy developer Gamida Cell. Crucially, the prepackaged reorganization plan provides no payment or other distribution to holders of common stock or the company's convertible preferred stock. The company has explicitly cautioned that it expects existing equity securities to have no value, a warning that has driven aggressive selling across the week.
Nasdaq Delisting and Index Removals
Compounding the distress, Nasdaq notified Karyopharm on November 4 that its securities would be delisted, citing bankruptcy-related public-interest concerns, uncertainty over residual equity value, and doubts about the company's ability to satisfy continued-listing requirements. The company said it would not appeal. Trading in the common stock is set to be suspended at the opening of business on November 11, after which shares are expected to trade over the counter under the ticker "KPTIQ." The stock has also been removed from Russell 2500 and S&P total-market indexes, forcing passive and index-tracking funds to sell and adding to the downward pressure.
Market Context and Trading Activity
Trading volume in KPTI has been extraordinarily elevated relative to its historical average throughout the week, with daily turnover spiking to tens of millions of shares as investors rushed to exit a position facing a complete loss. The move has diverged sharply from the broader market and from the wider biotech complex, underscoring that this is a company-specific, event-driven liquidation rather than sector sentiment. With the stock trading well below one dollar and every meaningful technical and moving-average level broken long ago, the shares now trade essentially as a distressed-claim proxy with prices bearing little relationship to any underlying recovery value.
What Comes Next for KPTI
Looking ahead, investors will monitor the bankruptcy court's approval of up to $55 million in debtor-in-possession financing and the bidding procedures that could draw competing offers for Karyopharm's assets. The company has also said it will present 48-week data from its Phase 3 SENTRY myelofibrosis study at the American Society of Hematology annual meeting, though any clinical progress would not flow through to existing common shareholders given the plan's treatment of equity. The planned transaction with Ayrmid is expected to close in the first quarter of 2027, subject to court approval. Key risks and uncertainties include whether the reorganization is completed, whether operations continue in the ordinary course, and whether existing equity retains any value at all.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from hundreds of strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see how algorithmic approaches are adapting to fast-moving and high-volatility situations like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for KPTI turns negative, indicating new downward trend
KPTI saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 86 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KPTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KPTI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KPTI entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for KPTI just turned positive on October 19, 2026. Looking at past instances where KPTI's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +83.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where KPTI advanced for three days, in 222 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.004) is normal, around the industry mean (3.498). P/E Ratio (-0.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.226) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. KPTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KPTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation
Industry Biotechnology
Advertisement